Efficacy and safety of different molecular targeted agents based on chemotherapy for gastric cancer patients treatment: a network meta-analysis.
Efficacy and safety of different molecular targeted agents based on chemotherapy for gastric cancer patients treatment: a network meta-analysis.
复制标题
基于胃癌患者化学疗法的不同分子靶向剂的功效和安全性：网络荟萃分析。
DOI：
10.18632/oncotarget.17192
复制
发表时间：
2017-07-18
期刊：
影响因子：
--
通讯作者：
Ge Q
中科院分区：
文献类型：
--
作者：
Ren Z;Sun J;Sun X;Hou H;Li K;Ge Q
越来越多的报道表明，分子靶向药物能够提高胃癌化疗的疗效。本网络荟萃分析旨在评价不同分子靶向药物的有效性和安全性，根据靶点分为6组，包括肝细胞生长因子受体（c-MET）、血管内皮因子及其受体（VEGF/VEGFR），人表皮生长因子受体2（HER 2），表皮生长因子受体（EGFR），哺乳动物雷帕霉素靶点（mTOR）和酪氨酸激酶抑制剂（TKI）。通过总生存期（OS）、无进展生存期（PFS）和总缓解率（ORR）评价这6组靶向药物的疗效结局。虽然他们的安全性进行了测量7不良事件，包括疲劳，贫血，呕吐，中性粒细胞减少症，血小板减少症，腹泻和恶心。经过广泛检索和严格纳入，共纳入23篇文献，其中HER 2和VEGF（R）在OS和PFS方面表现突出，是最有效的两种靶向药物。然而，它们与严重的不良事件相关，包括疲劳、中性粒细胞减少和腹泻。因此，在应用过程中应谨慎使用。结论：VEGF（R）和HER 2有可能成为其生存疗效的最佳靶点药物，但在应用中应注意与其相关的不良事件。
Increasing numbers of reports have been published to demonstrate that molecular targeted agents are able to improve the efficacy of chemotherapy in gastric cancer. This network meta-analysis aimed to evaluate the efficacy and safety of different molecular targeted agents, which were divided into six groups based on the targets including hepatocyte growth factor receptor (c-MET), vascular endothelial factor and its receptor (VEGF/VEGFR), human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), mammalian target of rapamycin (mTOR) and tyrosine kinase inhibitor (TKI). These six groups of targeted agents were evaluated for their efficacy outcomes measured by overall survival (OS), progression-free survival (PFS) and overall response rate (ORR). While their safety was measured 7 adverse events, including fatigue, anaemia, vomiting, neutropenia, thrombocytopenia, diarrhea and nausea. A total of 23 articles were included after extensive searching and strict inclusion, HER2 and VEGF(R) turned out to be the two most effective targeted drugs for their outstanding performance in OS and PFS. However, they were associated with severe adverse events, including fatigue, neutropenia and diarrhea. Therefore, they should be used with caution during their application. In conclusion, VEGF(R) and HER2 have the potential to be the optimal target agents for their survival efficacy, while the adverse events associated with them should be paid attention in application.
登录
查看更多内容
DOI：
10.1007/s10120-014-0351-5
发表时间：
2015-01
期刊：
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
影响因子：
--
作者：
Shen L;Li J;Xu J;Pan H;Dai G;Qin S;Wang L;Wang J;Yang Z;Shu Y;Xu R;Chen L;Liu Y;Yu S;Bu L;Piao Y
通讯作者：
Piao Y
影响因子：
51.1
作者：
Wilke, Hansjochen;Muro, Kei;Ohtsu, Atsushi
通讯作者：
Ohtsu, Atsushi
影响因子：
--
作者：
Xu, Chong-De
通讯作者：
Xu, Chong-De
影响因子：
45.3
作者：
Ohtsu, Atsushi;Shah, Manish A.;Kang, Yoon-Koo
通讯作者：
Kang, Yoon-Koo
DOI：
10.1016/s0197-2456(99)00026-4
发表时间：
1999-10-01
期刊：
CONTROLLED CLINICAL TRIALS
影响因子：
--
作者：
Clark, HD;Wells, GA;Laupacis, A
通讯作者：
Laupacis, A